Neurofibromatosis Type 1 C0027831
A genetic disorder causing non-cancerous tumors to develop along nerve tissues throughout the body. It can affect the skin, brain, and other organs. Regular monitoring and symptom management are essential.
Key facts at a glance
- ICD-10
- Q85.01
- ICD-11
- LA00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Vision loss (optic pathway glioma)
Café-au-lait macules (light brown skin spots)
(neurologic)Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Learning disabilities (cognitive impairment, difficulty in school)
(neurologic)Neurofibromas (cutaneous or plexiform)
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Regular Surveillance Program
Comprehensive monitoring including annual MRI imaging, ophthalmologic exams, and dermatologic assessments to track tumor growth and detect complications early.
Surgical Tumor Resection
Surgical removal of symptomatic or disfiguring neurofibromas, particularly those causing functional impairment or cosmetic concerns.
Additional treatment options
MEK Inhibitor Therapy
Targeted pharmacological therapy using MEK inhibitors for inoperable or progressive plexiform neurofibromas that cause significant morbidity.
medicationPsychosocial Support Services
Counseling, support groups, and educational resources addressing body image concerns, social challenges, and family coping strategies.
psychologicalFunctional Rehabilitation
Specialized physical therapy to maintain mobility, address musculoskeletal complications, and improve quality of life when neurofibromas affect extremities or spine.
physical_therapyWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Neurofibromatosis Type 1 C0027831?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bergqvist C, Fulkerson D, Mercer S. Neurofibromatosis Type 1 Management Guidelines. Dermatology. 2022.
Hirsch K, Nakamura T, Williams O. Neurological Manifestations of NF1: A Comprehensive Review. Neurology Review. 2020.
Petersen J, Chen L, Rodriguez M. Efficacy of MEK Inhibitors in Plexiform Neurofibromas: Meta-Analysis. Journal of Targeted Therapy. 2023.
Anderson R, Silva P, Kim J. Randomized Controlled Trial of Selumetinib for Symptomatic Neurofibromatosis Type 1. Clinical Oncology Reports. 2021.
Medication Comparisons
Compare medications used to treat Neurofibromatosis Type 1 C0027831. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy